The cross-talk between estrogen receptor and peroxisome proliferator-activated receptor gamma in thyroid cancer

Cancer

Volumn 120, Issue 1, 2014, Pages 142-153

  Chu, Ryan ^a   Van Hasselt, Andrew ^a   Vlantis, Alexander C ^a   Ng, Enders K W ^a   Liu, Shirley Y W ^a   Fan, Michael Dahua ^a   Ng, Siu Kwan ^a   Chan, Amy B W ^a   Liu, Zhimin ^b   Li, Xin Ying ^c   Chen, George G ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

apoptosis; estrogen receptors; peroxisome proliferator activated receptor gamma; rosiglitazone; thyroid cancer

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE 3; DNA NUCLEOTIDYLEXOTRANSFERASE; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; HUMAN; HUMAN CELL; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CANCER; THYROID CARCINOMA; WESTERN BLOTTING;

APOPTOSIS; ESTROGEN RECEPTORS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; THYROID CANCER;

APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENE KNOCKDOWN TECHNIQUES; HUMANS; PPAR GAMMA; RECEPTOR CROSS-TALK; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; THYROID NEOPLASMS; TRANSFECTION;

EID: 84890795863     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28383     Document Type: Article

References (27)

1. Rahbari R, Zhang L, Kebebew E,. Thyroid cancer gender disparity. Future Oncol. 2010; 6: 1771-1779.
2. Chen GG, Zeng Q, Tse GM,. Estrogen and its receptors in cancer. Med Res Rev. 2008; 28: 954-974.
3. Lee ML, Chen GG, Vlantis AC, et al. Induction of thyroid papillary carcinoma cell proliferation by estrogen is associated with an altered expression of Bcl-xL. Cancer J. 2005; 11: 113-121. (Pubitemid 44698822)
4. Zeng Q, Chen GG, Vlantis AC, van Hasselt CA,. Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor-ERK pathway. Cell Prolif. 2007; 40: 921-935. (Pubitemid 350135201)
5. Zeng Q, Chen G, Vlantis A, Tse G, van Hasselt C,. The contributions of oestrogen receptor isoforms to the development of papillary and anaplastic thyroid carcinomas. J Pathol. 2008; 214: 425-433. (Pubitemid 351350536)
6. Heikkila A, Hagstrom J, Maenpaa H, et al. Loss of estrogen receptor beta expression in follicular thyroid carcinoma predicts poor outcome. Thyroid. 2013; 23: 456-465.
7. Gearing KL, Gottlicher M, Teboul M, Widmark E, Gustafsson JA,. Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci U S A. 1993; 90: 1440-1444. (Pubitemid 23058188)
8. Chen Y, Wang SM, Wu JC, Huang SH,. Effects of PPARgamma agonists on cell survival and focal adhesions in a Chinese thyroid carcinoma cell line. J Cell Biochem. 2006; 98: 1021-1035. (Pubitemid 43993414)
9. Copland JA, Marlow LA, Kurakata S, et al. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene. 2006; 25: 2304-2317.
10. Aldred MA, Morrison C, Gimm O, et al. Peroxisome proliferator-activated receptor gamma is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas. Oncogene. 2003; 22: 3412-3416. (Pubitemid 36713738)
11. Ying H, Suzuki H, Zhao L, Willingham MC, Meltzer P, Cheng SY,. Mutant thyroid hormone receptor beta represses the expression and transcriptional activity of peroxisome proliferator-activated receptor gamma during thyroid carcinogenesis. Cancer Res. 2003; 63: 5274-5280. (Pubitemid 37139841)
12. Wang X, Kilgore MW,. Signal cross-talk between estrogen receptor alpha and beta and the peroxisome proliferator-activated receptor gamma1 in MDA-MB-231 and MCF-7 breast cancer cells. Mol Cell Endocrinol. 2002; 194: 123-133. (Pubitemid 35291927)
13. Catalano S, Mauro L, Bonofiglio D, et al. In vivo and in vitro evidence that PPARgamma ligands are antagonists of leptin signaling in breast cancer. Am J Pathol. 2011; 179: 1030-1040.
14. Kebebew E, Lindsay S, Clark OH, et al. S. Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer. Thyroid. 2009; 19: 953-956.
15. Smallridge RC, Copland JA, Brose MS, et al. Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. J Clin Endocrinol Metab. 2013; 98: 2392-2400.
16. Antonelli A, Fallahi P, Ulisse S, et al. New targeted therapies for anaplastic thyroid cancer. Anticancer Agents Med Chem. 2012; 12: 87-93.
17. Chen GG, Liu ZM, Vlantis AC, et al. Heme oxygenase-1 protects against apoptosis induced by tumor necrosis factor-alpha and cycloheximide in papillary thyroid carcinoma cells. J Cell Biochem. 2004; 92: 1246-1256. (Pubitemid 44264233)
18. Liu ZM, Hasselt CA, Song FZ, et al. Expression of functional metallothionein isoforms in papillary thyroid cancer. Mol Cell Endocrinol. 2009; 302: 92-98.
19. Li MY, Lee TW, Yim AP, Chen GG,. Function of PPARgamma and its ligands in lung cancer. Crit Rev Clin Lab Sci. 2006; 43: 183-202. (Pubitemid 43860450)
20. Di Vito M, De Santis E, Perrone GA, et al. Overexpression of estrogen receptor-alpha in human papillary thyroid carcinomas studied by laser-capture microdissection and molecular biology. Cancer Sci. 2011; 102: 1921-1927.
21. Magri F, Capelli V, Rotondi M, et al. Expression of estrogen and androgen receptors in differentiated thyroid cancer: an additional criterion to assess the patient's risk. Endocr Relat Cancer. 2012; 19: 463-471.
22. Dong W, Li J, Huang Y, Zhang H, Shan Z, Teng W,. Differential expression patterns of estrogen receptor (ER)-β splice variants between papillary thyroid cancer and nodular thyroid goiter. Med Sci Monit. 2012; 18: BR351-BR355.
23. Hebrant A, Dom G, Dewaele M, et al. mRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switch [serial online]. PLoS One. 2012; 7: e37807.
24. Evans JJ, Crist HS, Durvesh S, Bruggeman RD, Goldenberg D,. A comparative study of cell cycle mediator protein expression patterns in anaplastic and papillary thyroid carcinoma. Cancer Biol Ther. 2012; 13: 776-781.
25. Russo R, Di Cara G, Albanese NN, et al. Differential proteomic and phenotypic behaviour of papillary and anaplastic thyroid cell lines. J Proteomics. 2013; 90: 115-125.
26. Keller H, Givel F, Perroud M, Wahli W,. Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Mol Endocrinol. 1995; 9: 794-804.
27. Surazynski A, Jarzabek K, Miltyk W, Wolczynski S, Palka J,. Estrogen-dependent regulation of PPAR-gamma signaling on collagen biosynthesis in adenocarcinoma endometrial cells. Neoplasma. 2009; 56: 448-454.